Company Filing History:
Years Active: 2003-2010
Title: Michael Wilsterman: Innovator in Cardiac Treatment
Introduction
Michael Wilsterman is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of cardiac treatment through his innovative research and development of new compounds. With a total of 3 patents to his name, Wilsterman is recognized for his dedication to improving patient outcomes in the realm of cardiac arrhythmias.
Latest Patents
Wilsterman's latest patents focus on oxabispidine compounds that are useful in the treatment of cardiac arrhythmias. These compounds are designed to provide prophylaxis and treatment for various types of arrhythmias, particularly atrial and ventricular arrhythmias. The compounds are characterized by a specific formula, wherein the components R, A, B, and G have defined meanings as described in the patent documentation.
Career Highlights
Michael Wilsterman is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to cardiac health.
Collaborations
Some of Wilsterman's notable coworkers include Gert Strandlund and Peder Svensson. Their collaborative efforts have played a crucial role in advancing the research and development of innovative treatments for cardiac conditions.
Conclusion
Michael Wilsterman's work in developing oxabispidine compounds showcases his commitment to innovation in cardiac treatment. His contributions are vital in the ongoing effort to improve therapies for patients suffering from arrhythmias.